Skip to content
Search

Latest Stories

Morningside Pharmaceuticals' Nik Kotecha named in top 50 most ambitious business leaders list

Dr Nik Kotecha, chairman of Morningside Pharmaceuticals, has been named in the LDC’s Top 50 Ambitious Business Leaders for 2021 list.

The list, which is supported by The Times, recognises and celebrates inspiring leaders from among the UK’s most successful and fast-growing businesses. Now in its fourth year, the 2021 programme was said to have received 600 nominations from across a diverse range of sectors.


Dr Kotecha’s Loughborough-based Morningside Pharmaceuticals was set up in the early 90s as a manufacturer and supplier of generic medicines to the UK and international export markets. Today, the company has over 240 generic and branded licenced medicines in the UK and EU, delivered twice daily to the NHS.

He is also chairman of the Randal Charitable Foundation which has contributed over £9m to significantly improve the lives of people in the UK and globally since it was established in 2017.

In his reaction to being included in a prestigious programme, Dr Kotecha said: “It is a great privilege and an honour to make this national list alongside so many talented business leaders and entrepreneurs.

"One of my passions is working with young entrepreneurs to help them develop the necessary skills and experience to create the success stories of tomorrow. I hope my story and experiences can inspire and encourage others to try new things and follow their entrepreneurial dreams.”

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less